CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Company profile
Website
CEO
Sean A. McCarthy
Employees
Incorporated
Location
Fiscal year end
Former names
CytomX Therapeutics, LLC
SEC CIK
IRS number
261870083
Latest filings (excl ownership)
D
$1.5M in equity / Series C Preferred Units, sold $1.5M, 40 investors
13 Feb 15
D
$2.5M in equity / Series B-1 Preferred Units, sold $1.42M, 25 investors
29 Apr 14
D
$2M in Series B-1 Preferred Units, sold $1.24M, 25 investors
10 Sep 12
D
$2.66M in equity, sold $2.66M, 32 investors
23 Sep 10
D/A
$2.5M in options, sold $2.5M, 19 investors
3 Mar 10
D/A
$1.75M in options, sold $1.63M, 2 investors
17 Dec 09
D/A
$1.75M in options, sold $1.5M, 9 investors
21 Oct 09
D
Exempt offering of security
4 Jun 09
Latest ownership filings
No filings